Asahi Kasei, GlaxoSmithKline and Johnson & Johnson helped the respiratory disease drug developer boost its overall funding to $150m.
Author: Thierry Heles
AkroStar attracts $78m in series A round
Existing investor Da Heng Qin contributed to a round that increased the semiconductor technology provider’s overall funding to $155m.
Ginkgo Bioworks gears up for $17.5bn merger
The Illumina-backed microbial technology producer will list on the Nasdaq Capital Market through the reverse takeover transaction.
Kin Insurance constructs series C
CSAA-backed digital home insurance provider Kin secured $63.9m to increase its overall funding to about $150m.
Oxford Nanopore orchestrates $270m round
Nikon contributed to a $270m round valuing the DNA sequencing eqiupment producer at $3.4bn as it prepares to pursue a public listing.
Aphea.Bio harvests more series B funding
ECBF has provided an extension for the pesticide and crop stimulant provider’s Group De Ceuster-bacekd series B round, which now stands at $21.8m.
Vaccitech shoots for US IPO
Alphabet, Tencent and Gilead Sciences are in line to achieve exits, after the vaccine developer filed to go public on the Nasdaq Global Market.
Syzygy signs off on $23m series B
Equinor Ventures helped the photocatalyst reactor developer boost its overall funding to $35m in a round led by Horizons Ventures.
Baraja bags series B funding
Newly minted strategic partner Hitachi Construction Machinery was among the investors in a $30.4m round for the lidar system developer.
Meatable meets investors for $47m series A
DSM Venturing was among the investors in a round that will help the lab-grown meat developer widen its product range.
Riva Health raises series A funds
UCHealth contributed to a $15.5m round for the cardiovascular data platform developer that was led by Menlo Ventures.
Amphista clambers to $53m series B
Eli Lilly and Novartis Venture Fund participated in a round that will support the progress of Amphista’s protein degradation drug candidates toward clinical trials.
Vaccitech accelerates to $168m series B
Tencent and Gilead Sciences took part in a round that will fund clinical trials for three of Vaccitech’s vaccine product candidates.
Northvolt cuts acquisition deal with Cuberg
Boeing HorizonX has exited Cuberg three years after investing in the battery cell technology developer.